CRD-4730 for Arrhythmia

(CPVT Trial)

Recruiting at 2 trial locations

Overseen By Jason Homsy, MD, Ph.D.

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Cardurion Pharmaceuticals, Inc.

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

12 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.

Are You a Good Fit for This Trial?

This trial is for people with a heart rhythm disorder called CPVT, confirmed by genetic testing and clinical symptoms. Participants must have specific types of irregular heartbeats during an exercise stress test and be on a stable dose of antiarrhythmic medication (except amiodarone) or unable to tolerate such therapy. They also need to follow contraceptive guidelines.

Inclusion Criteria

I follow all birth control requirements.

I have been diagnosed with CPVT due to a specific genetic mutation.

I have frequent irregular heartbeats during exercise tests.

What Are the Treatments Tested in This Trial?

Interventions

• CRD-4730

Trial Overview The study tests CRD-4730's safety, how the body processes it, and its effects in patients with CPVT. It's a double-blind trial where participants get two doses of CRD-4730 and one placebo at random across three periods without knowing which they're receiving.

How Is the Trial Designed?

Group I: Dose 2 Experimental Treatment 1 Intervention

CRD 4730 Dose 2 Tablet

Group II: Dose 1 Experimental Treatment 1 Intervention

CRD-4730 Dose 1 Tablet

Group III: Dose 3 Placebo Group 1 Intervention

Placebo tablet to match CRD-4730

Who Is Running the Clinical Trial?

Cardurion Pharmaceuticals, Inc.

Lead Sponsor

Trials

6

Recruited

740+